Drugs that encourage the mobilization of hematopoietic stem cells in the bone marrow, including the TAT-HOXB4H protein to the peripheral blood, and medicine in order to improve the hematopoietic stem cell transplant patients, radiation therapy patient or recovery time of chemotherapy patients
The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
